Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA demethylating agents suppress preclinical models of synovial sarcoma

29 Apr 2025

Abstract excerpt

Synovial sarcoma is an aggressive soft-tissue cancer driven by the chimeric SS18::SSX fusion oncoprotein, which disrupts chromatin remodeling by combining two antagonistic transcriptional regulators. SS18 participates in BAF complexes that open chromatin, while the SSX genes are cancer-testis antigens that interface with chromatin decorated with monoubiquitinated histone H2A placed by polycomb repressive complex...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Sarcoma Diagnosis and Treatment

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40299558
DOI: 10.1172/jci190855

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA demethylating agents suppress preclinical models of synovial sarcomaPMID 40299558Read ↗

Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial SarcomaSemantic proximity Read ↗

Synovial Sarcoma: Recent Discoveries as a Roadmap to New Avenues for TherapySemantic proximity Read ↗

Molecular and epigenetic oncogenesis in synovial sarcoma: implications for cancer biology, diagnosis and treatmentSemantic proximity Read ↗

Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial SarcomaSemantic proximity Read ↗

Synovial Sarcoma Chromatin Dynamics Reveal a Continuum in SS18:SSX ReprogramingSemantic proximity Read ↗

Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial SarcomaSemantic proximity Read ↗

Genetic and Molecular Heterogeneity of Synovial Sarcoma and Associated Challenges in TherapySemantic proximity Read ↗

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcomaSemantic proximity Read ↗

ATR Is a Therapeutic Target in Synovial SarcomaSemantic proximity Read ↗

SUMO2 Inhibition Reverses Aberrant Epigenetic Rewiring Driven by Synovial Sarcoma Fusion Oncoproteins and Impairs SarcomagenesisSemantic proximity Read ↗

Histone Deacetylase Inhibitors Reverse SS18-SSX–Mediated Polycomb Silencing of the Tumor Suppressor <i>Early Growth Response 1</i> in Synovial SarcomaSemantic proximity Read ↗

Opposing immune and genetic forces shape oncogenic programs in synovial sarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.